Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 122 (6) , 1212-1219
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prospective Audit of Exudative Age-Related Macular Degeneration: 12-Month Outcomes in Treatment-Naïve EyesInvestigative Ophthalmology & Visual Science, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDEDRetina, 2011
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2010
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO StudyAmerican Journal of Ophthalmology, 2009
- Ranibizumab According to Need: A Treatment for Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006